Genocea Beats Investor Claims It Hid Truth About Herpes Drug
By Aaron Leibowitz (December 6, 2018, 7:55 PM EST) -- A Massachusetts federal judge dismissed a proposed investor class action Thursday against Genocea Biosciences Inc., saying accusations that the company hid negative test results before announcing it could not finance ongoing trials for a genital herpes immunotherapy were not sufficiently supported for the case to proceed.
The case largely rested on the investors' claim that the Cambridge-based company deliberately withheld the results of six-month followup tests for the drug's second phase of clinical trials in early 2017. But U.S. District Judge Patti B. Saris said in her order that, because the company later released 12-month testing results that did not cause...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!